The UK National Screening Committee (NSC) defines screening as a way of identifying people who are apparently healthy but may be at higher risk of a disease.[3] Effective screening can help to prevent deaths, disabilities and improve quality of life.[2] In addition, where the opportunity SB431542 manufacturer cost of providing screening is balanced by costs avoided in future health care, screening can also indirectly contribute to improving the economy of both individuals and society. However, a systematic review conducted by Jepson et al. in 2000[4] demonstrated that uptake of screening varied across different screening programmes and was influenced by a variety of patient characteristics including

gender, age and education. It reported that interventions that could potentially increase uptake included those that removed financial barriers.

Interventions that provided opportunistic screening were also found to increase uptake in some studies.[5-7] In most countries worldwide, community pharmacies are generally easily accessible; they are distributed throughout rural and urban locations and people do not usually have to book an appointment to visit the pharmacist. In the UK, for example, around 90% of the population visits a community pharmacy at least once each year.[8] Internationally, people are being encouraged see more to go to their community pharmacist for health advice.[9-11] Pharmacists already respond to their customers’ requests, advising on treatment of symptoms and providing health promotion advice.[12] Furthermore, community pharmacies are recognised locations where people seek help for the management of minor illnesses, the symptoms of which can often resemble early signs of some of the NCDs mentioned above. For these reasons, community pharmacies may be suitable settings for provision of screening programmes to facilitate earlier diagnosis of previously unrecognised conditions, or identification of risk factors for major diseases, especially opportunistic screening services. The aim of this systematic review was to assess the published evidence about community pharmacy-based screening

interventions for detection of major diseases in community pharmacy users. The objectives were: (1)  To identify and summarise the main components of community pharmacy-based screening interventions. Published Rolziracetam reports of randomised controlled trials (RCTs) of community pharmacy-based interventions are limited in number,[13] an observation that was confirmed by an initial scoping search. The current systematic review, therefore, considered all possible study designs including RCTs, quasi-experimental studies and observational studies. Study participants could include any user of community pharmacies irrespective of age, race, gender and health status. Any community pharmacy-based screening intervention that aimed to identify people with, or at risk from, a major disease was considered for inclusion.